Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. reduced its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 97.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,158 shares of the medical device company's stock after selling 369,178 shares during the period. Jefferies Financial Group Inc.'s holdings in Tandem Diabetes Care were worth $330,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Hood River Capital Management LLC bought a new stake in shares of Tandem Diabetes Care during the 4th quarter worth approximately $46,035,000. Jacobs Levy Equity Management Inc. increased its position in Tandem Diabetes Care by 189.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock valued at $59,830,000 after acquiring an additional 1,086,337 shares during the period. Brown Advisory Inc. bought a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $32,889,000. Park West Asset Management LLC raised its position in shares of Tandem Diabetes Care by 49.5% during the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock worth $57,632,000 after acquiring an additional 530,000 shares during the last quarter. Finally, Baillie Gifford & Co. raised its holdings in Tandem Diabetes Care by 235.7% during the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company's stock worth $26,875,000 after purchasing an additional 523,843 shares during the last quarter.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TNDM shares. Royal Bank of Canada lowered their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Stifel Nicolaus lowered their target price on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Barclays dropped their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Robert W. Baird reduced their target price on shares of Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a research report on Thursday, May 1st. Finally, Citigroup upped their price objective on shares of Tandem Diabetes Care from $20.00 to $24.00 and gave the company a "neutral" rating in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $35.86.

Tandem Diabetes Care Stock Up 2.0%

Tandem Diabetes Care stock traded up $0.41 during trading hours on Tuesday, hitting $20.63. The stock had a trading volume of 1,558,344 shares, compared to its average volume of 1,493,875. The stock's 50-day moving average price is $19.45 and its 200-day moving average price is $27.05. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $15.75 and a 12-month high of $53.64. The stock has a market capitalization of $1.37 billion, a P/E ratio of -10.69 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business's revenue was up 22.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.65) earnings per share. Equities research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.